Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

BACKGROUND: Brentuximab vedotin is an anti-CD30 antibody–drug conjugate that has been approved for relapsed and refractory Hodgkin’s lymphoma. METHODS: We conducted an open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin’s lym...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:N Engl J Med
Main Authors: Connors, J.M., Jurczak, W., Straus, D.J., Ansell, S.M., Kim, W.S., Gallamini, A., Younes, A., Alekseev, S., Illés, Á., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K.J., Bartlett, N.L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P.L., Cunningham, D., Rosta, A., Josephson, N.C., Song, E., Sachs, J., Liu, R., Jolin, H.A., Huebner, D., Radford, J.
Format: Artigo
Sprog:Inglês
Udgivet: 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5819601/
https://ncbi.nlm.nih.gov/pubmed/29224502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1708984
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker